Sugi Predict

Sugi Predict / Compounds / SCHEMBL187136

SCHEMBL187136

SCHEMBL187136

COc1ccc([N+](=O)[O-])cc1C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 3/20 0.66
▸ HTT P42858 4/20 0.62
▸ ALDH1A1 P00352 7/20 0.62
▸ TSHR P16473 2/20 0.62
▸ CYP3A4 P08684 4/20 0.58
▸ LMNA P02545 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ MAPT P10636 7/20 0.55
▸ CYP19A1 P11511 1/20 0.54
▸ PTGS2 P35354 1/20 0.54
▸ MEN1 O00255 5/20 0.54
▸ KMT2A Q03164 5/20 0.54
▸ CYP1A2 P05177 2/20 0.54
▸ CYP2D6 P10635 2/20 0.54
▸ CYP2C9 P11712 2/20 0.54
▸ CYP2C19 P33261 2/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ PKM P14618 1/20 0.51
▸ POLB P06746 1/20 0.50
▸ NPC1 O15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9185260 0.86 ALDH1A1 (0.64) TDP1HTTALDH1A1TSHRCYP3A4
SCHEMBL14499401 0.86 TDP1 (0.54) TDP1HTTALDH1A1TSHRCYP3A4
SCHEMBL30676003 0.86 TDP1 (0.54) TDP1HTTALDH1A1TSHRCYP3A4
SCHEMBL265440 0.85 HTT (0.68) TDP1HTTALDH1A1TSHRCYP3A4
SCHEMBL527567 0.84 HTT (0.72) TDP1HTTALDH1A1TSHRCYP3A4
SCHEMBL29441283 0.84 HTT (0.72) TDP1HTTALDH1A1TSHRCYP3A4
SCHEMBL4231911 0.83 ALDH1A1 (0.54) TDP1HTTALDH1A1TSHRCYP3A4
SCHEMBL10914421 0.83 ALDH1A1 (0.61) TDP1HTTALDH1A1TSHRCYP3A4
SCHEMBL27842355 0.83 ALDH1A1 (0.60) TDP1HTTALDH1A1TSHRCYP3A4
SCHEMBL10961730 0.83 TDP1 (0.51) TDP1HTTALDH1A1TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114507252-B Novel method for synthesizing arylsilane compound 广西大学 2023-10-27 — — CN claimed
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF EPIVARIO INC (US) 2026-03-26 — — US disclosed
US-12441689-B2 ACSS2 inhibitors and methods of use thereof EPIVARIO, INC. (US) 2025-10-14 — — US disclosed
EP-3653296-B1 INTERMETALLIC COMPOUND, HYDROGEN STORAGE/RELEASE MATERIAL, CATALYST AND METHOD FOR PRODUCING AMMONIA JAPAN SCIENCE & TECH AGENCY (JP) 2023-12-13 — — EP disclosed
CN-114507252-B Novel method for synthesizing arylsilane compound 广西大学 2023-10-27 — — CN disclosed
US-11712680-B2 Process for reducing aromatic nitro compounds with supported catalyst KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2023-08-01 — — US disclosed
US-20230084752-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-03-16 — — US disclosed
US-20220401927-A1 PROCESS FOR REDUCING AROMATIC NITRO COMPOUNDS WITH SUPPORTED CATALYST KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2022-12-22 — — US disclosed
US-11452992-B2 Iron oxide supported rhodium catalyst for nitroarene reduction KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2022-09-27 — — US disclosed
CN-114507252-A Synthesis method of novel aryl silane compound 广西大学 2022-05-17 — — CN disclosed
EP-1081138-A1 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds Maruishi Pharmaceutical Co., Ltd. (JP) 2001-03-07 — — EP disclosed
EP-0580550-B1 Oxamic acid derivatives as hypocholesteremic agents CIBA GEIGY AG (CH) 1997-10-22 — — EP disclosed
US-5654468-A ANTILIPID, ANTICHOLESTEROL AGENTS CIBA-GEIGY CORPORATION (US) 1997-08-05 — — US disclosed
US-5569674-A ANTICHOLESTEROL AGENTS CIBA-GEIGY CORPORATION (US) 1996-10-29 — — US disclosed
EP-0335274-B1 Formation of nitrophenyl ethers from polyols and nitroanisoles DOW CHEMICAL CO (US) 1996-03-13 — — EP disclosed
US-5401772-A Anticholesterol agents with aromatic amines CIBA-GEIGY CORPORATION (US) 1995-03-28 — — US disclosed
EP-0580550-A1 Oxamic acid derivatives as hypocholesteremic agents CIBA-GEIGY AG (CH) 1994-01-26 — — EP disclosed
US-4960950-A Formation of nitrophenyl ethers from polyols and nitroanisoles THE DOW CHEMICAL COMPANY (US) 1990-10-02 — — US disclosed
EP-0335274-A2 Formation of nitrophenyl ethers from polyols and nitroanisoles THE DOW CHEMICAL COMPANY (US) 1989-10-04 — — EP disclosed
US-3963698-A Alkylations employing in situ generation of diazoalkane alkylation reagents MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1976-06-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11712680-B2 Process for reducing aromatic nitro compounds with supported catalyst ARG2, NDUFS5, NDUFS7 TDP1 2491/4885HTT 800/4885ALDH1A1 2712/4885
US-20220401927-A1 PROCESS FOR REDUCING AROMATIC NITRO COMPOUNDS WITH SUPPORTED CATALYST ARG2, NDUFS5, NDUFS7 TDP1 2491/4885HTT 800/4885ALDH1A1 2712/4885
US-11452992-B2 Iron oxide supported rhodium catalyst for nitroarene reduction ARG2, NOS2, NDUFS7 TDP1 2889/4885HTT 1730/4885ALDH1A1 2798/4885
US-20230084752-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, ADSS2, GLS2 TDP1 3712/4885HTT 4810/4885ALDH1A1 347/4885
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ACSL3 TDP1 4000/4885HTT 4847/4885ALDH1A1 1031/4885
US-12441689-B2 ACSS2 inhibitors and methods of use thereof ACSS2, ADSS2, GLS2 TDP1 3712/4885HTT 4810/4885ALDH1A1 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.